INDICATED FOR THE TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS.
A DOSE OF 1.5 G/M2 IS GIVEN UNDILUTED BY INTRAVENOUS INFUSION OVER 2 HOURS IN ADULTS, ON DAYS 1, 3, AND 5 OF A 21-DAY CYCLE.
CHILDREN : NELARABINE IS GIVEN UNDILUTED BY INTRAVENOUS INFUSION OVER 1 HOUR, AT A DOSE OF 650 MG/M2 DAILY FOR 5 DAYS, AND REPEATED EVERY 21 DAYS.
TREATMENT IS GENERALLY CONTINUED UNTIL THERE WAS EVIDENCE OF DISEASE PROGRESSION, THE PATIENT EXPERIENCED UNACCEPTABLE TOXICITY, THE PATIENT BECAME A CANDIDATE FOR BONE MARROW TRANSPLANT, OR THE PATIENT NO LONGER CONTINUED TO BENEFIT FROM TREATMENT.